PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of ocular surface disorders.

Abstract To evaluate the safety and efficacy of the surgical use of plasma rich in growth factors fibrin membrane (mPRGF) in different ocular surface pathologies.Fifteen patients with different corneal and conjunctival diseases were included in the study. Patients were grouped according to the use of mPRGF as graft (corneal and/or conjunctival) or dressing; they were also grouped according to the surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, superficial keratectomy, corneal perforation, and pterygium). Best corrected visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF AT (PRGF membrane absorption time), and the healing time of the epithelial defect (HTED) were evaluated throughout the clinical follow-up time. Safety assessment was also performed reporting all adverse events.mPRGF showed a total closure of the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients (13.3%). The mean follow-up time was 11.1 ± 4.2 (4.8-22.8) months, the mean ICT was 2.5 ± 1.1 (1.0-4.0) months, the mean mPRGF AT was 12.4 ± 2.0 (10.0-16.0) days, and for the global HTED the mean was 2.9 ± 1.2 (1-4.8) months. Results showed an improvement in BCVA in all patients, with an overall improvement of 2.9 in Vision Lines. The BCVA significantly improved (P < .05) in the groups of corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of epithelial defect was significantly reduced (P < .05) in patients treated only with the mPRGF in comparison to those which mPRGF therapy was associated to the amniotic membrane. The IOP remained stable (P > .05) throughout the clinical follow-up time. No adverse events were reported after mPRGF use.The mPRGF is effective and safe as coadjuvant treatment in surgeries related with ocular surface disorders, being an alternative to the use of amniotic membrane. The mPRGF accelerates tissue regeneration after ocular surface surgery thus minimizing inflammation and fibrosis.
PMID
Related Publications

Limbal stem cell transplantation: an evidence-based analysis.

Human amniotic membrane in the reconstruction of the ocular surface.

Cultured corneal epithelia for ocular surface disease.

Evaluation of the role of ProKera in the management of ocular surface and orbital disorders.

Amniotic membrane graft in ocular surface disease. Prospective study with 31 cases.

Authors

Mayor MeshTerms

Biological Dressings

Keywords
Journal Title medicine
Publication Year Start




PMID- 29702971
OWN - NLM
STAT- MEDLINE
DCOM- 20180514
LR  - 20180516
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 17
DP  - 2018 Apr
TI  - Plasma rich in growth factors membrane as coadjuvant treatment in the surgery of 
      ocular surface disorders.
PG  - e0242
LID - 10.1097/MD.0000000000010242 [doi]
AB  - To evaluate the safety and efficacy of the surgical use of plasma rich in growth 
      factors fibrin membrane (mPRGF) in different ocular surface pathologies.Fifteen
      patients with different corneal and conjunctival diseases were included in the
      study. Patients were grouped according to the use of mPRGF as graft (corneal
      and/or conjunctival) or dressing; they were also grouped according to the
      surgical subgroup of intervention (persistent corneal ulcer [PCU], keratoplasty, 
      superficial keratectomy, corneal perforation, and pterygium). Best corrected
      visual acuity, intraocular pressure (IOP), inflammation control time (ICT), mPRGF
      AT (PRGF membrane absorption time), and the healing time of the epithelial defect
      (HTED) were evaluated throughout the clinical follow-up time. Safety assessment
      was also performed reporting all adverse events.mPRGF showed a total closure of
      the defect in 13 of 15 patients (86.7%) and a partial closure in 2 patients
      (13.3%). The mean follow-up time was 11.1 +/- 4.2 (4.8-22.8) months, the mean ICT
      was 2.5 +/- 1.1 (1.0-4.0) months, the mean mPRGF AT was 12.4 +/- 2.0 (10.0-16.0) 
      days, and for the global HTED the mean was 2.9 +/- 1.2 (1-4.8) months. Results
      showed an improvement in BCVA in all patients, with an overall improvement of 2.9
      in Vision Lines. The BCVA significantly improved (P &lt; .05) in the groups of
      corneal graft and dressing. In the PCU subgroup (6 patients), the healing time of
      epithelial defect was significantly reduced (P &lt; .05) in patients treated only
      with the mPRGF in comparison to those which mPRGF therapy was associated to the
      amniotic membrane. The IOP remained stable (P &gt; .05) throughout the clinical
      follow-up time. No adverse events were reported after mPRGF use.The mPRGF is
      effective and safe as coadjuvant treatment in surgeries related with ocular
      surface disorders, being an alternative to the use of amniotic membrane. The
      mPRGF accelerates tissue regeneration after ocular surface surgery thus
      minimizing inflammation and fibrosis.
FAU - Sanchez-Avila, Ronald M
AU  - Sanchez-Avila RM
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Merayo-Lloves, Jesus
AU  - Merayo-Lloves J
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Riestra, Ana C
AU  - Riestra AC
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Berisa, Silvia
AU  - Berisa S
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Lisa, Carlos
AU  - Lisa C
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Sanchez, Jose Alfonso
AU  - Sanchez JA
AD  - Fundacion de Investigacion Oftalmologica, Instituto Universitario Fernandez-Vega,
      Oviedo.
FAU - Muruzabal, Francisco
AU  - Muruzabal F
AD  - University Institute for Regenerative Medicine and Oral Implantology, UIRMI
      (UPV/EHU-Fundacion Eduardo Anitua).
AD  - Biotechnology Institute.
FAU - Orive, Gorka
AU  - Orive G
AD  - University Institute for Regenerative Medicine and Oral Implantology, UIRMI
      (UPV/EHU-Fundacion Eduardo Anitua).
AD  - Biotechnology Institute.
AD  - Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
      University of the Basque Country.
AD  - Networking Biomedical Research Center on Bioengineering, Biomaterials and
      Nanomedicine, CIBER-BBN, SLFPB-EHU, Vitoria, Spain.
FAU - Anitua, Eduardo
AU  - Anitua E
AD  - University Institute for Regenerative Medicine and Oral Implantology, UIRMI
      (UPV/EHU-Fundacion Eduardo Anitua).
AD  - Biotechnology Institute.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 9001-31-4 (Fibrin)
SB  - AIM
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Amnion
MH  - *Biological Dressings
MH  - Eye Diseases/*surgery
MH  - Female
MH  - Fibrin/*therapeutic use
MH  - Humans
MH  - Intercellular Signaling Peptides and Proteins/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Ophthalmologic Surgical Procedures/adverse effects/*methods
MH  - Platelet-Rich Plasma
MH  - Retrospective Studies
MH  - Tissue Transplantation/adverse effects/*methods
MH  - Visual Acuity
PMC - PMC5944476
EDAT- 2018/04/29 06:00
MHDA- 2018/05/15 06:00
CRDT- 2018/04/29 06:00
PHST- 2018/04/29 06:00 [entrez]
PHST- 2018/04/29 06:00 [pubmed]
PHST- 2018/05/15 06:00 [medline]
AID - 10.1097/MD.0000000000010242 [doi]
AID - 00005792-201804270-00003 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Apr;97(17):e0242. doi: 10.1097/MD.0000000000010242.